Primal-dual for classification with rejection (PD-CR): a novel method for classification and feature selection-an application in metabolomics studies.

Journal: BMC bioinformatics
Published Date:

Abstract

BACKGROUND: Supervised classification methods have been used for many years for feature selection in metabolomics and other omics studies. We developed a novel primal-dual based classification method (PD-CR) that can perform classification with rejection and feature selection on high dimensional datasets. PD-CR projects data onto a low dimension space and performs classification by minimizing an appropriate quadratic cost. It simultaneously optimizes the selected features and the prediction accuracy with a new tailored, constrained primal-dual method. The primal-dual framework is general enough to encompass various robust losses and to allow for convergence analysis. Here, we compare PD-CR to three commonly used methods: partial least squares discriminant analysis (PLS-DA), random forests and support vector machines (SVM). We analyzed two metabolomics datasets: one urinary metabolomics dataset concerning lung cancer patients and healthy controls; and a metabolomics dataset obtained from frozen glial tumor samples with mutated isocitrate dehydrogenase (IDH) or wild-type IDH.

Authors

  • David Chardin
    Transporters in imaging and Radiotherapy in Oncology (TIRO), Direction de la Recherche Fondamentale (DRF), Institute des sciences du vivant Fréderic Joliot, Commissariat à l'Energie Atomique et aux énergies alternatives (CEA), Université Côte d'Azur (UCA), Nice, France.
  • Olivier Humbert
    Department of Nuclear Medicine, Centre Georges-François Leclerc, Dijon, France.
  • Caroline Bailleux
    Transporters in imaging and Radiotherapy in Oncology (TIRO), Direction de la Recherche Fondamentale (DRF), Institute des sciences du vivant Fréderic Joliot, Commissariat à l'Energie Atomique et aux énergies alternatives (CEA), Université Côte d'Azur (UCA), Nice, France.
  • Fanny Burel-Vandenbos
    Central Laboratory of Pathology, University Hospital and Institute of Biology Valrose, Inserm U1091 - CNRS UMR7277, University Côte d'Azur, Nice, France.
  • Valerie Rigau
    Department of Pathology and Oncobiology, University Hospital, Montpellier, France.
  • Thierry Pourcher
  • Michel Barlaud